Since 2004, the Publications Committee has been charged with developing and publishing various publications, including the SMFM Consult Series and the SMFM Clinical Guidelines series published in the American Journal of Obstetrics & Gynecology. The Publications Committee collaborates with other Societies and Colleges to develop joint publications and statements, as appropriate. The Committee plans topics, selects authors, and reviews each completed paper before it is submitted for an internal SMFM review process and then for publication. All Committee members have filed conflict of interest statements with SMFM. Any conflicts have been resolved through a process approved by the Executive Board. To facilitate transparency in SMFM's guideline development process, a brief overview of the key stages in development is provided here. Feedback for SMFM Publications is welcome at pubs@smfm.org
Abstract Pregnancy in individuals with a mechanical heart valve has been classified as very high risk because of a substantially increased risk of maternal mortality or severe morbidity. Lifelong therapeutic anticoagulation is a principal component of the medical management of mechanical heart... Continue Reading
Prenatal ultrasound is an indispensable tool used by obstetrical care providers to assist in the everyday care of their pregnant patients. Alongside advancements in imaging, the electronic systems that support this technology have become more advanced. However, it is currently difficult for these... Continue Reading
The processes of diagnosis and management involve clinical decision-making. However, decision making is often affected by cognitive biases that can lead to medical errors. This statement presents a framework of clinical thinking and decision-making and shows how these processes can be bias-prone.... Continue Reading
SMFM endorses the SFP Interim clinical recommendations: self-managed abortion. Download PDF TAGS: respiratory, second trimester abortion, Early Pregnancy Loss,Late Pregnancy Loss, Vaccination CATEGORIES: SMFM Endorsed Partner Publication Continue Reading
Original Article TAGS: prenatal diagnosis, fetal testing, genetic screening, genetic CATEGORIES: SMFM Endorsed Partner Publication Continue Reading
SMFM supports the new ACOG ACOG Statement on FDA Warning on Genetic Non-Invasive Prenatal Screening Tests and continues to support existing SMFM guidance on NIPT. Original Article Continue Reading
Chronic hypertension occurs in approximately 2% of pregnancies in the United States and remains a major cause of maternal and perinatal morbidity and mortality. Specifically, chronic hypertension is associated with an increased risk of preeclampsia, pulmonary edema, acute kidney injury,... Continue Reading
Profound inequities in maternal and infant outcomes based on race exist, and the maternal-fetal medicine community has an important role in eliminating these disparities. Accurately employing race and ethnicity as social constructs within research that guides clinical practice is essential to... Continue Reading
Hospital readmission is considered a core measure of quality in healthcare. Readmission soon after hospital discharge can result from suboptimal care during the index hospitalization or from inadequate systems for post discharge care. For many conditions, readmission is associated with a high rate... Continue Reading
The Society for Maternal-Fetal Medicine seeks to ensure excellence in obstetrical outcomes for all people who desire or experience pregnancy, including people with diverse sexual and gender identities. The Society commits to the use of practices in clinical and research settings that affirm the... Continue Reading
Abstract The use of assisted reproductive technology has increased in the United States in the past several decades. Although most of these pregnancies are uncomplicated, in vitro fertilization is associated with an increased risk for adverse perinatal outcomes primarily caused by the increased... Continue Reading
Severe hypertension in pregnancy is a medical emergency. Although expeditious treatment within 30 to 60 minutes is recommended to reduce the risk of maternal death or severe morbidity, treatment is often delayed by >1 hour. In this statement, we propose a quality metric that facilities can use... Continue Reading
